ALVOAlvotech

Nasdaq alvotech.com


$ 12.05 $ 0.05 (0.42 %)    

Friday, 28-Jun-2024 14:09:52 EDT
QQQ $ 480.99 $ -2.40 (-0.5 %)
DIA $ 390.15 $ -1.41 (-0.36 %)
SPY $ 545.09 $ -2.55 (-0.47 %)
TLT $ 92.42 $ -1.31 (-1.4 %)
GLD $ 215.05 $ -0.89 (-0.41 %)
$ 12
$ 11.86
$ 0.00 x 0
$ 0.00 x 0
$ 11.84 - $ 12.05
$ 6.70 - $ 18.00
35,378
na
3.2B
$ 0.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alvotech-inks-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-eylea-ldhd-in-europe

Advanz Pharma secures rights to commercialize Alvotech's biosimilar candidate for Eylea® in Europe Advanz Pharma will le...

 alvotech-sa-may-offer-and-sell-ordinary-shares-of-up-to-75m-from-time-to-time-entered-into-open-market-sale-agreement-with-jefferies-relating-to-sale-of-ordinary-shares

- SEC Filing

 alvotech-and-stada-extend-partnership-through-avt03-biosimilar-candidate-addition

Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facili...

 alvotech-secures-965m-refinancing-deal-to-boost-financial-flexibility-and-support-product-launches

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

 barclays-maintains-overweight-on-alvotech-raises-price-target-to-22

Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and raises the price target from $20 to $22.

 alvotech-now-sees-fy24-revenue-of-400m-500m-est-318575m

Alvotech tightened guidance for EBIDTA to $100 - $150 million for the full year.

 alvotech-q1-2024-gaap-eps-089-up-from-124-yoy

Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.89) per share. This is a 28.23 percent increase over losses of $(1.24) ...

 stocks-hold-steady-on-mixed-fed-remarks-first-solar-rallies-bitcoin-falls-below-70000-whats-driving-markets-tuesday

It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.

Core News & Articles

"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing...

Core News & Articles

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI ...

 alvotech-receives-fda-approval-for-selarsdi-for-moderate-to-severe-plaque-psoriasis

Alvotech receives FDA approval for Selarsdi for moderate to severe plaque psoriasisAdult patients with:moderate to severe plaqu...

 aehr-test-systems-reports-preliminary-results-joins-dyne-therapeutics-united-airlines-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

 alvotech-announces-increased-the-companys-share-capital-by-an-amount-of-130k-by-issuing-13m-ordinary-shares

Alvotech (NASDAQ:ALVO) (the "Company"), a global biotech company specializing in the development and manufacture of bio...

 barclays-maintains-overweight-on-alvotech-raises-price-target-to-20

Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and raises the price target from $17 to $20.